PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases – today announced that it has appointed Brian Koh, M.D., as its Chief Medical Officer. In this new role, Dr. Koh will be responsible for developing and executing the company’s clinical development and medical strategy, serving on PrognomiQ’s Executive Team.
Read the full article here.
November 5, 2024
PrognomiQ Announces $34 Million Series D Financing to Advance Development of Early Detection Test for Lung Cancer with Multi-omics Platform
Read More
January 8, 2024
PrognomiQ’s Latest Research Demonstrates the Potential of its Multi-omics Liquid Biopsy Platform in Early-Stage Detection of Lung Cancer
Read More
